Intellia Therapeutics (NTLA) Other Gross PP&E Adjustments (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Other Gross PP&E Adjustments data on file, last reported at -$106.2 million in Q1 2026.

• Other Gross PP&E Adjustments for Q1 2026 came in at -$106.2 million, up 24.74% year-over-year; the trailing twelve-month figure through Mar 2026 was -$106.2 million (up 24.74% YoY), and the FY2025 annual result was -$31.9 million, up 81.97% from the prior year.
• Other Gross PP&E Adjustments slipped to -$106.2 million in Q1 2026 per NTLA's latest filing, from -$31.9 million in the prior quarter.
• Over five years, Other Gross PP&E Adjustments peaked at -$31.9 million in Q4 2025 and troughed at -$177.0 million in Q4 2024.
• A 5-year average of -$108.3 million and a median of -$109.0 million in 2024 frame the typical range for Other Gross PP&E Adjustments.
• The sharpest annual moves came in 2022 and 2025: Other Gross PP&E Adjustments sank 1960.19% in 2022, then soared 81.97% in 2025.
• A 5-year view of Other Gross PP&E Adjustments shows it stood at -$94.5 million in 2022, then grew by 22.55% to -$73.2 million in 2023, then tumbled by 141.99% to -$177.0 million in 2024, then soared by 81.97% to -$31.9 million in 2025, then sank by 232.85% to -$106.2 million in 2026.
• Business Quant data shows NTLA's Other Gross PP&E Adjustments at -$106.2 million in Q1 2026, -$31.9 million in Q4 2025, and -$120.6 million in Q3 2025.